Research & Discovery
Reconstruction of DNA repair-deficient xeroderma pigmentosum skin in the laboratory
This breakthrough development, published in July 2001, should enable research to be conducted without direct experimentation on XP patients. The full title of this work is:
“Clues to epidermal cancer proneness revealed by reconstruction of DNA repair-deficient xeroderma pigmentosum skin in vitro” by Françoise Bernerd, Daniel Asselineau, Corinne Vioux, Odile Chevallier-Lagente, Bakar Bouadjar, Alain Sarasin, and Thierry Magnaldo
T4N5 Liposome Lotion Study Findings Published
AGI Dermatics has published the T4N5 study results.
This DNA repair lotion reduced the occurrence of the most common form of skin cancer, basal cell carcinoma, by 30% and a pre-cancerous form of skin cancer, actinic keratosis, was reduced by 68%.
The study was conducted among patients with xeroderma pigmentosum because they lack DNA repair and develop skin cancer in childhood.
The new drug, T4N5 Liposome Lotion – trade name DimericineT – was developed by Applied Genetics Inc. Dermatics. It delivers a purified DNA repair enzyme in liposomes to the skin to reverse sun damage to DNA and thereby prevent skin cancer. The drug supplements the missing enzyme in this disease and reduces the rate at which cancers develop.
Daniel Yarosh, Ph.D., president of AGI Dermatics, presented his findings at the March American Academy of Dermatology Meeting.